Skip to content
Craig Doig

Craig Doig

Associate Professor

School of Science & Technology

Staff Group(s)
Bioscience

Role

Craig is an Associate Professor of Metabolic Health. He is interested in the basic mechanistic biology of both cells and tissue systems, working to apply this understanding towards treatment strategies targeting human disease. The laboratory are focussed upon the mechanisms and metabolic roles of NAD+ consuming enzymes and interactions with steroid hormone signaling.

Career overview

Prior to his career in academia, Craig was an analytical scientist working with 3M Health Care, Astra-Zeneca, Merck and Sanofi-Aventis. For his doctoral training Craig was located at Roswell Park Cancer Institute, Buffalo, New York USA. Here he studied mechanisms of transcriptional control in cancer, employing epigenetic techniques and DNA methylation analysis. As a postdoctoral researcher, Craig trained within the fields of endocrinology and molecular metabolism at the Centre for Endocrinology Diabetes & Metabolism and the Institute of Metabolism & Systems Research at University of Birmingham. His work revealing the roles of steroid hormone biochemistry and its impacts upon tissues including brown adipose and skeletal muscle. These projects have helped define current understanding of endocrinology, metabolism and mitochondrial function.

Research areas

Craig is strongly interested in the regulation of physiology, endocrinology, epigenetic signalling and how they impact metabolic pathways in health and disease.

Fully funded PhD Studentships are available in this lab - Please email Craig directly for further information.

Opportunities arise to carry out postgraduate research towards an MPhil / PhD in the areas identified above. Further information may be obtained on the NTU Research Degrees website https://www.ntu.ac.uk/research/research-degrees-at-ntu

Publications

  1. Contribution of local regeneration of glucocorticoids to tissue steroid pools. Khan S, Livingstone DEW, Zielinska A, Doig CL, Cobice DF, Esteves CL, Man JTY, Homer NZM, Seckl JR, MacKay CL, Webster SP, Lavery GG, Chapman KE, Walker BR, Andrew R.  J Endocrinol. 2023.
  2. PARP1 mediated PARylation contributes to myogenic progression and glucocorticoid transcriptional response. Tan A, Younis AZ, Evans A, Creighton JV, Coveney C, Boocock D, Sale C, Lavery GG, Coutts A, Doig CL. Cell Death and Discovery. 2023.
  3. Rapid isolation of respiring skeletal muscle mitochondria using nitrogen cavitation. Younis AZ, Lavery GG, Christian M, Doig CL. Frontiers in Physiology. 2023.
  4. Contribution of local versus systemic regeneration of glucocorticoids to tissue steroid pools. Khan S, Livingstone DEW, Zielinska A, Doig CL, Cobice DF, Esteves C, Man J, Homer NZM, Seckl JR, MacKay CL, Webster SP, Lavery GG, Walker BR, Andrew R. Journal of Endocrinology. Accepted 2023.
  5. Spatial proteomics reveals heterogeneity of neural marker expression underpinning the metabolic response to high fat diet induced myopathy in mice. Hardowar L, Vadakekolathu Narayanan J, Rutella S, Hulse R, Doig CL. Journal of Molecular Endocrinology.Under revision 2023.
  6. Lavilla CJ, Billacura MP, Hanna K, Boocock DJ, Coveney C, Miles AK, Foulds GA, Murphy A, Tan A, Jackisch L, Sayers SR, Caton PW, Doig CL, McTernan PG, Colombo SL, Sale C, Turner MD. Carnosine protects stimulus-secretion coupling through prevention of protein carbonyl adduction events in cells under metabolic stress. Free Radical Biology and Medicine. 2021.
  7. Cartwright DM, Oakey LA, Fletcher RS, Doig CL, Heising S, Larner DP, Nasteska D, Berry CE, Heaselgrave SR, Ludwig C, Hodson DJ, Lavery GG, Garten A. Nicotinamide riboside has minimal impact on energy metabolism in mouse models of mild obesity. Journal of Endocrinology. 2021.
  8. Induction of the nicotinamide riboside kinase NAD+ salvage pathway in a model of sarcoplasmic reticulum dysfunction. Doig CL, Zielinska AE, Fletcher RS, Oakey LA, Elhassan YS, Garten A, Cartwright D, Heising S, Alsheri A, Watson DG, Prehn C, Adamski J, Tennant DA, Lavery GG. Skeletal Muscle. 2020.
  9. Metabolic tracing reveals novel adaptations to skeletal muscle cell energy production pathways in response to NAD + depletion. Oakey LA, Fletcher RS, Elhassan YS, Cartwright DM, Doig CL, Garten A, Thakker A, Maddocks ODK, Zhang T, Tennant DA, Ludwig C, Lavery GG. Wellcome Open Research. 2020.
  10. 11β-HSD1 plays a critical role in trabecular bone loss associated with systemic glucocorticoid therapy. Fenton CG, Doig CL, Fareed S, Naylor A, Morrell AP, Addison O, Wehmeyer C, Buckley CD, Cooper MS, Lavery GG, Raza K, Hardy RS. Arthritis Research & Therapy. 2019.
  11. Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures. Elhassan YS, Kluckova K, Fletcher RS, Schmidt MS, Garten A, Doig CL, Cartwright DM, Oakey L, Burley CV, Jenkinson N, Wilson M, Lucas SJE, Akerman I, Seabright A, Lai YC, Tennant DA, Nightingale P, Wallis GA, Manolopoulos KN, Brenner C, Philp A, Lavery GG.Cell Reports. 2019.
  12. Nicotinamide Nucleotide Transhydrogenase as a Novel Treatment Target in Adrenocortical Carcinoma. Chortis V, Taylor AE, Doig CL, Walsh MD, Meimaridou E, Jenkinson C, Rodriguez-Blanco G, Ronchi CL, Jafri A, Metherell LA, Hebenstreit D, Dunn WB, Arlt W, Foster PA. Endocrinology. 2018.
  13. Glucocorticoids Reprogram β-Cell Signaling to Preserve Insulin Secretion. Fine NHF, Doig CL, Elhassan YS, Vierra NC, Marchetti P, Bugliani M, Nano R, Piemonti L, Rutter GA, Jacobson DA, Lavery GG, Hodson DJ. Diabetes. 2018.
  14. Nicotinamide riboside kinases display redundancy in mediating nicotinamide mononucleotide and nicotinamide riboside metabolism in skeletal muscle cells. Fletcher RS, Ratajczak J, Doig CL, Oakey LA, Callingham R, Da Silva Xavier G, Garten A, Elhassan YS, Redpath P, Migaud ME, Philp A, Brenner C, Canto C, Lavery GG. Molecular Metabolism. 2017.
  15. Cellular and genetic models of H6PDH and 11β-HSD1 function in skeletal muscle. Zielinska AE, Fletcher RS, Sherlock M, Doig CL, Lavery GG. Cell Biochemistry & Function. 2017.
  16. 11β-HSD1 Modulates the Set Point of Brown Adipose Tissue Response to Glucocorticoids in Male Mice. Doig CL, Fletcher RS, Morgan SA, McCabe EL, Larner DP, Tomlinson JW, Stewart PM, Philp A, Lavery GG. Endocrinology. 2017.
  17. 11β-Hydroxysteroid dehydrogenase type 1 within muscle protects against the adverse effects of local inflammation. Hardy RS, Doig CL, Hussain Z, O'Leary M, Morgan SA, Pearson MJ, Naylor A, Jones SW, Filer A, Stewart PM, Buckley CD, Lavery GG, Cooper MS, Raza K. Journal of Pathology. 2016.
  18. Male 11β-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease. Larner DP, Morgan SA, Gathercole LL, Doig CL, Guest P, Weston C, Hazeldine J, Tomlinson JW, Stewart PM, Lavery GG. Endocrinology. 2016.
  19. Glucocorticoids and 11β-HSD1 are major regulators of intramyocellular protein metabolism. Morgan SA, Hassan-Smith ZK, Doig CL, Sherlock M, Stewart PM, Lavery GG. Journal of Endocrinology. 2016.
  20. Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells. Doig CL, Battaglia S, Khanim FL, Bunce CM, Campbell MJ. Journal of Steroid Biochemistry & Molecular Biology. 2016.
  21. TNFα-mediated Hsd11b1 binding of NF-κB p65 is associated with suppression of 11β-HSD1 in muscle. Doig CL, Bashir J, Zielinska AE, Cooper MS, Stewart PM, Lavery GG.  Journal of Endocrinology. 2014.
  22. Epigenetic distortion to VDR transcriptional regulation in prostate cancer cells. Singh PK, Doig CL, Dhiman VK, Turner BM, Smiraglia DJ, Campbell MJ. Journal of Steroid Biochemistry & Molecular Biology. 2013.
  23. Recruitment of NCOR1 to VDR target genes is enhanced in prostate cancer cells and associates with altered DNA methylation patterns. Doig CL, Singh PK, Dhiman VK, Thorne JL, Battaglia S, Sobolewski M, Maguire O, O'Neill LP, Turner BM, McCabe CJ, Smiraglia DJ, Campbell MJ. Carcinogenesis. 2013.
  24. A switch in hepatic cortisol metabolism across the spectrum of non-alcoholic fatty liver disease. Ahmed A, Rabbitt E, Brady T, Brown C, Guest P, Bujalska IJ, Doig C, Newsome PN, Hubscher S, Elias E, Adams DH, Tomlinson JW, Stewart PM. PLoS One. 2012.
  25. Epigenetic control of a VDR-governed feed-forward loop that regulates p21(waf1/cip1) expression and function in non-malignant prostate cells. Thorne JL, Maguire O, Doig CL, Battaglia S, Fehr L, Sucheston LE, Heinaniemi M, O'Neill LP, McCabe CJ, Turner BM,  Campbell MJ. Nucleic Acids Research. 2011.
  26. Elevated NCOR1 disrupts PPARalpha/gamma signaling in prostate cancer and forms a targetable epigenetic lesion. Battaglia S, Maguire O, Thorne JL, Hornung LB, Doig CL, Liu S, Sucheston LE, Bianchi A, Khanim FL, Gommersall LM, Coulter HS, Rakha S, Giddings I, O'Neill LP, Cooper CS, McCabe CJ, Bunce CM, Campbell MJ. Carcinogenesis. 2010.
  27. Pituitary tumor transforming gene binding factor: a new gene in breast cancer. Watkins RJ, Read ML, Smith VE, Sharma N, Reynolds GM, Buckley L, Doig C, Campbell MJ, Lewy G, Eggo MC, Loubiere LS, Franklyn JA, Boelaert K, McCabe CJ. Cancer Research. 2010.

REVIEW ARTICLES

  1. Tan A, Doig CL. NAD+ Degrading Enzymes, Evidence for Roles During Infection. Frontiers Molecular Biosciences. 2021.
  2. Creighton JV, de Souza Goncalves L, Artiolo GG, Tan D, Elliot-Sale KJ, Turner MD, Doig CL, Sale C. Physiological Roles of carnosine in myocardial function and health. Advances in Nutrition. 2022.
  3. PARP Inhibitors: Staying on Target? Doig CL, Lavery GG.Cell Chemical Biology. 2016.
  4. Molecular roles of ADP-Ribosylation in the infection and immune response to Trypanosoma Cruzi.  Dowling J, Doig CL. Pathogens. 2023.